Tag Archives: CVC

Hot Investor Mandate 4: Germany-Based CVC with a Global Presence Invests in Innovative Medical Technologies Globally, Including Imaging & PoC and In Vitro Diagnostics

7 Jun

A corporate venture firm is headquartered in Munich, Germany, with additional offices worldwide. The fund invests in medical technology companies that are strategically relevant to the corporate’s interests. Investments in equity rounds range from $1-5 million and are made worldwide.

The firm’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the firm focuses on products used in a hospital setting. The firm also invests in digital health solutions that add value to imaging and diagnostics, such as data-as-a-service products. The firm is potentially interested in medical robotics. The firm will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The firm generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: Japanese CVC with USA Offices Invests in Novel Pharmaceutical, Medical Device, and Digital Health Technologies

24 May

A corporate venture arm of a diversified business based in Tokyo is focused on investing in various sectors, including healthcare. The team is based in offices in both the West and East Coast. The fund has an evergreen structure looking to allocate between $1-$3 million per deal initially and up to $5 million over the life of the investment. The firm is seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, DDS, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Corporate Venture Arm of Leading Netherlands’ Telecom Service Provider Looking for Data and Software-Based Healthcare Technologies

19 Apr

Established in 2015, a corporate venture capital investment arm of a leading telecom and ICT service provider has interests in a variety of sectors in relation to their corporate activities, one of them being Digital Health. The firm manages a €70M revolving venture fund via which the firm invests in fast growing technology companies (Series A-C). In addition, the firm selectively invest in venture capital investment funds that complement the firm’ direct investment strategy and provide broader access to new technology companies and partnership opportunities. In January 2018, the firm for example initiated an early stage (seed) investment fund with multiple Dutch investors.

The firm aims to create value-creating partnerships with innovative technology companies providing access to capital, industry expertise, professional network and customer channels. The firm mainly focuses on opportunities based in Europe but is also interested to get in touch with companies which are located in USA and Canada, as long as they have an interest in expanding their commercial activities to the Netherlands. The firm’s initial ticket size typically ranges from €0.5M to €3M for minority stakes, building long-term partnerships, ultimately aiming for external exits, not acquisitions. The firm is open to both leading and co-investing, depending on the proposition. While the firm does not aim for a specific number of investments, the firm has made 6 investments per year since establishment.

The firm is highly interested in B2B/B2C software-based technology companies. The firm will only consider medical or diagnostic hardware companies that have a strong data or software component. The firm is especially interested in technologies that enable easier and smarter health management for patients and or medical professionals (i.e. self-monitoring devices for chronic disease management with real-time data accessibility, preventative healthcare, etc.). The firm is also interested in propositions that focus on (cyber) security solutions and or propositions that create efficiencies/cost-reductions within health organizations.

The firm seeks technologies that have a strategic fit or enough potential for a future collaboration with the firm’s health business, that fall under the firm’s sectors of interest. The firm prefers to work with management teams with a proven track record and wants to see market traction/validation, with at least €0.5M in annual revenues.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Life Science Investor Mandate 3: CVC of Large Pharma Looking for Therapeutics and Companion Diagnostics

7 May

The corporate venture capital arm of a large pharmaceutical company is currently looking to make equity investments into early stage life science companies. The firm has the ability to allocate up to $10 million dollars per company, generally in milestone driven tranches. The firm is able to invest in companies from around the globe and is actively seeking new investment opportunities.

The firm is looking for early stage companies working with therapeutics and companion diagnostics. The firm is open to review both small molecules and biologics as well as companies working with single assets or platform technologies. The firm seeks to invest in indication areas including Immunology, Oncology, Immunoncology, MS, and Fertility. The firm generally looks for companies with assets that are pre-clinical or in Phase I of clinical trials.

The firm is looking for privately held companies with experienced management teams. The firm looks to take an active role following investing generally taking at least a board seat. The firm is willing to both lead rounds and co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

<span>%d</span> bloggers like this: